U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921928) titled 'Study for AZD4360 in Participants With Advanced Solid Tumours' on March 25.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Study Start Date: May 23
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer
Gastroesophageal Junction Cancer
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma
Intervention:
DRUG: AZD4360
Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
Recruitment Status: NOT_YET_RECRUITING...